Overview
The 25th Annual International Congress on the Future of Breast Cancer® West will provide clinicians with cutting-edge updates on recent advances in the treatment of breast cancer, from preclinical breakthroughs to changes in clinical treatment paradigms. Novel agents and improved regimens, coupled with more in-depth molecular and phenotypic subtyping, are driving the future of breast cancer therapy. This dynamic program will focus on the practical implications of emerging data for patient care in the clinic. Recent data and their clinical impact are highlighted throughout the program, with expert perspectives on how to apply the evidence to individualize therapy for patients with breast cancer. Current areas of controversy or uncertainty will also be debated, with discussion of ongoing clinical trials and investigational approaches designed to address these questions.
This conference provides a unique opportunity for medical, surgical, and radiation oncologists and other health care professionals to learn from and interact with international leaders in the field of breast cancer to increase knowledge, apply new data to practice, and, ultimately, improve patient outcomes.
Program Co-Chairs
Sara A. Hurvitz, MD, FACP; Joyce O'Shaughnessy, MD
To view full profile, click on the Program Co-Chairs tab above.
Sara A. Hurvitz, MD, FACP
Professor
Senior Vice President and Director, Clinical Research Division
Smith Family Endowed Chair in Women’s Health
Fred Hutch Cancer Center
Seattle, WA
Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, TX
Click the button below to view all faculty presenters.
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 17.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 17.0 Contact Hours.
Medical Oncologists (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This activity is supported by educational grants from Exact Sciences Corporation; Hologic, Inc; Novartis Pharmaceuticals Corporation; Puma Biotechnology, Inc; Stemline Therapeutics, Inc; and Tolmar Pharmaceuticals.
Additional support for the Featured Symposia is provided by educational grants from AstraZeneca; Daiichi Sankyo, Inc; Lilly; and Stemline Therapeutics, Inc.
PER is proud to partner with The Arizona Clinical Oncology Society and Nevada Oncology Society.
